About Dr. Rosenberg
Boca Raton, FL January 14, 2011: Dr. Mark Rosenberg, Medical Director of the Institute for Healthy Aging and Director of the Integrative Cancer Therapies Fellowship with the American Academy of Anti-Aging Medicine, announced the preliminary findings of a novel technique for treating advanced-stage cancer.
Using a process that Dr. Rosenberg
calls, "Cancer pH Manipulation Therapy," he
was able to completely normalize tumor markers in four weeks in a patient with metastatic endometrial carcinoma without the use of chemotherapy.
has begun treating a second patient with this therapy, who has been diagnosed with stage IIIC primary peritoneal carcinoma.
tumor marker had been rapidly rising prior to Dr. Rosenberg's
protocol, Dr. Rosenberg
achieved a 40% reduction in tumor markers in just two weeks.
treatment targets cancers that feed on glucose, and process the glucose through a mechanism known as glycolysis.
Most cancers (both stem cells and non-stem cells) rely more heavily on glycolysis relative to normal tissue.
The end product of glycolysis is lactic acid.
Based on Dr. Rosenberg's
in-vitro study at University of Miami
developed an oral protocol which blocks three mechanisms that cancer cells use to efflux lactic acid.
Effluxing lactic acid is essential for the cancer cells to prevent apoptosis (programmed cell death); in addition, as the cancer cells efflux lactic acid and acidify their extracellular ilieu, the resulting acidity promotes the aggressiveness of the cancer.
After Dr. Rosenberg
ensures that the acid pumps are blocked, he
literally feeds the cancer cells by infusing high dose glucose.
As the cancer cells feed, they create lactic acid that is unable to be pumped out of the cells.
In Dr. Rosenberg's
words, "the more they eat the faster they die."
About Mark Rosenberg, M.D.
For the past 15 years Dr. Mark Rosenberg
has combined modern medicine with nutrition, exercise, and physiology to create a natural program for healthier living.
Dr. Rosenberg received his undergraduate degree from University of Pennsylvania and graduated from Georgetown University School of Medicine.
then completed his
residency in emergency medicine in San Antonio, Texas at Brooke Army Medical Center
, where he
won the award of "Teacher and Resident of the Year."
has been involved with drug research since 1991.
Having studied the mechanisms of cancer treatment failure, the following concept has become blatantly apparent to Dr. Rosenberg
There are many substances that are toxic to cancer cells in vitro (outside of the body, in a culture medium), including chemotherapy and intravenous antioxidant therapy.
These therapies, however, are more often than not, ineffective inside the body.
The primary reason for the ineffectiveness is that tumor blood flow is poor, resulting in a tumor that actually receives very little of the cytotoxic therapy that is being administered.
In addition, poor tumor blood flow is associated with higher grade tumors and greater incidence of metastasis.
Knowing this, Dr. Rosenberg
developed a novel protocol that integrates standard chemotherapeutic regimens with non-toxic natural supplemental regimens.
has since concentrated his
efforts on improving blood flow to the cancer, while administering cytotoxic intravenous antioxidant therapy.
In addition to using vasodilating therapy such as carbogen and isosorbide dinitrate, Dr. Rosenberg
has just been granted approval status for an IND (investigational new drug) using Angiotensin II.
Angiotensin II is frequently used in Japan in conjunction with chemotherapy to improve tumor blood flow.
was featured on Fox News
for inducing remission in a patient with cancer that had spread from the lungs to the liver and spine.
In 1997, Dr. Rosenberg became a diplomate of the American College of Anti-Aging Medicine.
has since become a highly sought-after speaker, lecturing frequently on topics such as integrative cancer therapy and anti-aging medicine.
In 2009, Dr. Rosenberg
regularly lectured in Asia, Europe, and the Middle East.
He published a physician's guide to the treatment of drug toxicities and served as a consultant to several hospitals for the treatment of drug overdoses.
In addition to drug research, he is avidly involved in supplement research, and has served as the Chief Science Officer for several supplement companies including VitalMax Vitamins.
Dr. Mark A Rosenberg serves as Director of the Fellowship in Integrative Cancer Therapy.